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 Abstract 
  Background/Aim:  Alzheimer’s disease (AD) causes impairment in memory and other cognitive 
functions as well as neuropsychiatric symptoms and limitations in the activities of daily living 
(ADL). The aim of this study was to examine whether demographic variables, dementia severity, 
ADL and neuropsychiatric symptoms are associated with cognition in very mild or mild AD. 
  Methods:  We analyzed the baseline data of 236 patients with very mild or mild AD participating 
in a prospective AD follow-up study (ALSOVA). The Consortium to Establish a Registry for Alz-
heimer’s Disease neuropsychological battery total score was used in the evaluation of the glob-
al cognitive performance.   Results:   Cognition was associated with dementia severity and ADL 
but not with neuropsychiatric symptoms. ADL functions were associated with both cognitive 
performance and neuropsychiatric symptoms.  Conclusion:  Even patients with very mild or mild 
AD may exhibit neuropsychiatric symptoms not related to cognitive impairment. The results of 
this study emphasize the importance of taking a multidimensional approach to the diagnostic 
and prognostic evaluation of AD patients already in the early stages of the disease. 
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 Introduction 
  Alzheimer’s disease (AD) is a progressive neurodegenerative disease which is character-
ized by impairment in cognitive and functional abilities as well as by neuropsychiatric symp-
toms. Cognitive impairment can include impairment in memory, visuospatial functions, 
language and executive functions. In addition, neuropsychiatric symptoms, such as depres-
sion, apathy and agitation, seem to be common already in early stages of AD and can have 
an impact on both patients’ and care-givers’ well-being   [1–3]  . Cognitive performance has 
been consistently associated with functional ability  [4–8] ; however, the association of neuro-
psychiatric symptoms with cognition and daily functioning is unclear   [7, 9–13]  , in spite of 
the fact that the amount of neuropsychiatric symptoms seems to increase in patients with 
more advanced dementia   [14, 15]  . Thus, more information is needed to elucidate how these 
features of AD are interrelated.
    The Consortium to Establish a Registry for Alzheimer’s Disease neuropsychological 
battery (CERAD-NB)  [16]  is a widely used, short and reliable measure of cognitive impair-
ment in AD patients   [17, 18]  . The method for calculating a total score for the CERAD-NB 
was published in 2005  [19] , and recent studies have supported both the validity and useful-
ness of the CERAD total score for the detection of mild cognitive impairment and demen-
tia   [20–22]   as well as for monitoring progression of AD dementia   [21]  . That is, it seems to 
be more valuable to use the total score than relying on single subtests. Though the Mini-
Mental State Examination (MMSE)   [23]   has been commonly used, it has been claimed to 
be of limited value as a screening instrument   [24, 25]   and in measuring progression of AD 
 [26] .
    The present study was designed to examine whether global cognitive performance as-
sessed by the CERAD total score is associated with dementia severity, activities of daily living 
(ADL) and neuropsychiatric symptoms in patients with very mild or mild AD.
  M e t h o d s  
 Subjects 
  A total of 241 patients with recently diagnosed very mild or mild AD participated in a 
prospective AD follow-up study (ALSOVA). The total follow-up period will be up to 5 years 
  [1, 2]  . The aim of the ALSOVA study is to elucidate the effects and cost-efficiency of psycho-
social rehabilitation. The study subjects were recruited from April 2002 to September 2006 
from the neurology departments of the University Hospital of Kuopio and North-Karelia 
Central Hospital and from the geriatric memory clinic of the Central Hospital of Central-
Finland.
    The patients were diagnosed at neurology departments or geriatric memory clinics ac-
cording to clinical practice, and the diagnosis of AD according to NINCDS-ADRDA guide-
lines   [27]   was verified by the research doctor. The baseline data were not used as part of the 
diagnostic procedure, but it is possible that same methods (e.g. CERAD) have been used. All 
subjects had very mild or mild dementia at baseline. Finnish speaking, community-dwelling 
individuals who were free of comorbid conditions that could have affected cognition and 
who had a loved one as their caregiver were included.
    Three subjects from the original study population of 241 subjects were excluded since 
they were found to have moderate AD, one subject had a diagnosis of Parkinson’s disease and 
another one suffered from blindness. Ultimately, 236 patients fulfilled the inclusion criteria 
for this part of the study.211
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  M e a s u r e s  
  The extensive data collected included age, gender, education, physical health, medica-
tion, household composition, living arrangements, general well-being, caregiver burden, de-
pression, quality of life and society resource utilization   [1, 2]  .
  The cognitive evaluation was performed with the CERAD-NB  [16]  and MMSE  [23] . The 
Finnish version of the CERAD-NB   [28]   consists of nine subtests; the Delayed Recall of Con-
structional Praxis and the Clock Drawing Test are additions to the original test battery. The 
total score for the CERAD-NB was calculated for each participant according to the subtest 
addition method   [19]  . The total score was obtained by summing the raw scores from the six 
subtests (Verbal Fluency Test, modified Boston Naming Test, Word List Memory, Word List 
Recall, Word List Recognition Discriminability and Constructional Praxis) into a total score 
(maximum 100 points) according to the original method.
    The Clinical Dementia Rating (CDR) scale is a rating scale for evaluating the severity of 
the memory disorder   [29, 30]  . The structured interview protocol includes six areas, and the 
scores in each of these sections are combined to obtain a composite score and a sum of box-
es (SOB) score. The Alzheimer’s Disease Cooperative Study – Activities of Daily Living In-
ventory (ADCS-ADL) is a set of informant-based items describing performance of ADL for 
patients with AD  [4] . The Neuropsychiatric Inventory (NPI) is an informant-based interview 
that assesses twelve behavioral disturbances occurring in dementia patients   [31]  . The total 
NPI score is the sum of the subscale scores (frequency   !   severity). Higher scores indicate 
more behavioral disturbance.
    Data were missing for one subject for Constructional Praxis, Delayed Constructional 
Praxis and Clock Drawing Test because of problems in vision and for another subject for the  
Word List Recognition because of difficulties understanding the test instructions. Thus, the 
data for the CERAD total score were missing for two subjects.
  Ethical  Considerations 
 The Ethics Committee of Kuopio University Hospital approved the ALSOVA study pro-
tocol. The study participants were recruited from three memory clinics serving three hospi-
tal districts. Potential participants received written and oral information of the study, and an 
initial visit was arranged soon after the diagnosis for those who consented to participate. The 
voluntary nature of participation and the confidentiality of data collected were emphasized. 
The informed consent form was signed by both the patients with AD and their caregivers. 
The caregivers also provided proxy consent on behalf of the individuals with AD.
  D a t a   A n a l y s i s  
  Descriptive statistics were used to summarize the variables studied and the characteris-
tics of the participants. The data were analyzed with SPSS for Windows 14.0 software package. 
The t test was used to compare cognition and severity of dementia and the Mann-Whitey U 
test to compare ADL and neuropsychiatric symptoms between men and women and between 
CDR 0.5 and 1 groups. Pearson’s correlation was used to analyze relations between the 
CERAD-NB, MMSE, CDR-SOB, age and education. Spearman’s correlation was used to ana-
lyze the ADCS-ADL or NPI scores. A p value   !  0.05 was considered statistically significant.
  R e s u l t s  
  Almost half of the study participants (n = 115, 48.7%) were men. Most of the patients 
(66.1%) had mild dementia (CDR = 1) and 33.9% had very mild dementia (CDR = 0.5). In 
70.3% of cases, the caregiver was a spouse, whereas in 23.7% of cases, the caregiver was a 212
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child. The remaining 6% of caregivers were siblings or children’s spouses. On average, the 
participants were recruited 5 months after diagnosis. Almost all patients (96.2%) were on AD 
medication, with 93.8% of them using acetylcholine esterase inhibitors and 6.2% using me-
mantine.   Table 1   shows the mean age, education in years, CDR-SOB score, CERAD total 
score, MMSE score, ADCS-ADL score and NPI total score. Only 18.2% of the participants 
had no neuropsychiatric symptoms, 21.6% had one symptom, 13.1% two and 47.0% displayed 
symptoms in at least three different NPI domains. The most common neuropsychiatric 
symptoms were apathy (48.3%), depression (36.4%) and irritability (33.9%).
    There was no significant difference in the CERAD total score, MMSE score, CDR-SOB 
score or NPI score between men and women. Women performed better on the ADCS-ADL 
than men (z = –4.287, p   !   0.001). Not surprisingly, participants with very mild dementia 
(CDR = 0.5) outperformed those with mild dementia (CDR = 1) on the CERAD total score 
(t(2,232) = 4.308, p   !   0.001) and MMSE score (t(2,234) = 5.886, p   !   0.001), received a lower 
NPI total score (z = –2.892, p = 0.028) and a greater ADCS-ADL score (z = –7.032, p   !   0.001; 
  table 1  ).   Table 2   shows the results of the correlation analyses between age and education and 
CERAD total, MMSE, CDR-SOB and ADCS-ADL scores. The length of education was pos-
itively correlated with the CERAD total score and the MMSE score, but there was no sig-
nificant correlation between age and the CERAD total score or age and the MMSE score. Age 
correlated negatively with ADCS-ADL scores, and education correlated negatively with 
CDR-SOB scores and positively with ADCS-ADL scores. NPI scores did not correlate with 
education or age.
      Table 2   shows the results of the correlation analyses between the CERAD total, MMSE, 
CDR-SOB, ADCS-ADL and NPI total scores. The CDR-SOB score was negatively correlated 
with the CERAD total and MMSE scores, whereas the ADCS-ADL score was positively cor-
related with the CERAD total and MMSE scores. We also analyzed the correlation between 
Table 1.   Demographic and clinical characteristics of the AD patients participating in the study
CDR 0.5
(n = 80)
CDR 1
(n = 156)
All
(n = 236)
p value*
Female, % 53.8 50 51.3
Age, years 73.8586.95
(56–87)
75.7586.26
(53–90)
75.1186.55
(53–90)
0.245
Education, years 8.1483.32
(1–18)
7.2583.25
(1–20)
7.5583.29
(1–20)
0.350
CERAD total score1 (scale 0–100) 56.09812.63
(25–96)
49.28810.77
(22–82)
51.58811.85
(22–96)
<0.001
MMSE score (scale 0–30) 23.2282.95
(16–30)
20.6283.34
(12–30)
21.583.44
(12–30)
<0.001
CDR-SOB score (scale 0–18) 2.6080.70
(1–3.5)
4.9181.13
(3–8)
4.1381.49
(1–8)
<0.001
ADCS-ADL score (scale 0–78) 69.6385.99
(50–78)
61.9188.78
(34–76)
64.5388.73
(34–78)
<0.001
NPI score (0–144) 6.3187.25
(0–32)
10.16810.63
(0–49)
8.8689.78
(0–49)
0.028
V  alues are mean 8 SD with ranges in parentheses, unless indicated otherwise.
* Pairwise comparisons of the difference between very mild (CDR = 0.5) and mild (CDR = 1) AD de-
mentia, significance of difference in two-tailed t test or Mann-Whitney U test, calculated by Bonferroni 
correction. 1 n = 234.213
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the CERAD total and ADCS-ADL scores separately for subjects with low education (  ^ 8 
years) and subjects with high education ( 6 9 years). The correlation was stronger in the more 
educated group (r = 0.351, p = 0.009) but was significant also in the low-educated group (r = 
0.186, p = 0.013). The ADCS-ADL score was negatively correlated with the CDR-SOB score. 
The NPI total score was not correlated with the CERAD total score or the MMSE score. We 
also analyzed the correlation between the CERAD total and NPI scores separately in low- 
and high-educated groups and got similar results. None of the NPI subscales was correlated 
with the CERAD total score and none of the CERAD subtests was correlated with the NPI 
total score. The NPI total score was positively correlated with CDR-SOB score and negative-
ly with ADCS-ADL scores.
  Discussion 
  In this study, we investigated correlations between the CERAD total score, ADL and 
neuropsychiatric measures in a large group of systematically documented AD patients with 
very mild or mild dementia. Almost all of them used medication for AD. They all partici-
pated in a longitudinal study focusing on the effects and cost-efficiency of early psychosocial 
rehabilitation. There have been very few studies using the CERAD total score to measure 
cognitive performance in AD patients. In our study, CERAD total score correlated with the 
MMSE. As expected, participants with clinical staging of very mild dementia (CDR = 0.5) 
outperformed those with mild dementia (CDR = 1). These findings are consistent with re-
sults from previous studies   [19, 21, 22]  .
    The influence of education on the results of the CERAD-NB subtests has been noted in 
many studies, but the influence of age and gender has varied across studies   [17, 19, 32–35]  . 
Consistent with data on the CERAD subtests for a sample of elderly Finns  [33] , our results in 
the AD sample revealed a correlation between the CERAD total score and education but not 
between the CERAD total score and age. There was no difference in the CERAD total score 
between genders. Our results are in agreement with those of previous studies about the im-
portance of taking into account the educational level of AD patients in any evaluation of 
cognitive performance conducted with the CERAD-NB.
    Although the mean NPI total score is relatively low, it can represent for example several 
occasional mild symptoms or two weekly moderate symptoms or one severe symptom. The 
Table 2. C  orrelations between demographic and clinical characteristics of the AD patients participating 
in the study
CERAD
total score†
MMSE 
score†
CDR-SOB 
score†
ADCS-ADL
score‡
NPI 
score‡
Education (years) 0.334*** 0.278*** –0.204* 0.357*** –0.092
Age (years) 0.062 0.035 0.159 –0.201* –0.073
CERAD total score 0.618*** –0.319*** 0.250*** –0.087
MMSE score –0.443*** 0.314*** 0.049
CDR-SOB score –0.580*** 0.231***
ADCS-ADL score –0.339***
* ** p < 0.001, * p < 0.05, calculated by Bonferroni correction. † Pearson’s product-moment correlation 
coefficient; ‡ Spearman’s rank correlation coefficient.214
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mean NPI score in our AD sample is consistent with previous studies with comparable 
groups of patients  [36] . We have previously reported that these symptoms have an impact on 
both patients’ and care-givers’ well-being already in early stages of AD   [1, 2]  . Studies in pa-
tients with mild cognitive impairment show that neuropsychiatric symptoms may be a pre-
dictor of conversion to AD   [37]  , which emphasizes the role of evaluation of these symptoms 
already in the early phase of the disease.
    There are very few studies where the CERAD total score was used as a measure of cog-
nitive function in the evaluation of associations between cognitive performance, functional 
ability and neuropsychiatric symptoms. In our study, cognition was significantly associated 
with ADL. These results are consistent with those from previous studies conducted with the 
CERAD total score  [22]  or other cognitive measures  [4, 5, 7–9] . Women received better scores 
in the ADCS-ADL, which probably reflects the traditional way to share housework in mar-
riages in this generation, and this needs to be taken into account when using ADL measures. 
An association was also detected between ADL and neuropsychiatric symptoms. There are 
many previous findings indicating that neuropsychiatric symptoms are associated with 
functional limitations   [6, 7, 11, 13]  , although some studies have found contrasting results 
 [5,  9] .
    Most reports in the literature indicate that behavioral symptoms and cognition are not 
related   [10, 11]   or that the relationship is weak   [7, 12]  . There is also evidence that any change 
in behavioral symptoms is independent from changes occurring in cognitive measures   [9]  . 
Instead, Harwood et al.   [6]   described a relationship between psychological and behavioral 
disturbances and MMSE scores. Our study, using the CERAD total score and MMSE score, 
indicates that neuropsychiatric symptoms were not correlated with cognitive performance. 
Our results are consistent with most of the previous evidence, showing that cognitive and 
behavioral disturbances are rather distinct entities in AD, at least in the mild stage of the 
disease. Although the correlations between other clinical characteristics (CERAD total, 
ADCS-ADL, NPI and CDR-SOB scores) were fairly modest (0.23–0.58), they were clearly 
significant and, on the contrary, the correlations between cognition and neuropsychiatric 
symptoms did not imply even a tendency of association.
    There are some limitations to this study. All patients and their caregivers voluntarily 
participated in this 5-year follow-up study and met regularly with the study nurse and psy-
chologist. Some of the subjects were randomly selected to participate in early psychosocial 
intervention. Therefore, this voluntary participation procedure may have produced a selec-
tion bias. Thus, this study population may not completely represent the general population 
of patients with very mild or mild AD. Andersen et al.   [38]   have reported that recruitment 
from clinical practice and population-based screening represent study samples with differ-
ent demographic characteristics.
    Our study population at baseline was homogenous in terms of recently diagnosed very 
mild or mild AD. Therefore, results cannot be generalized to patients with more advanced 
dementia. The educational level of older persons in Finland is often lower than in other West-
ern countries, and this needs to be considered when interpreting results. Despite these limi-
tations, our results strongly support previous studies.
  The strength of our study was the use of several different measures and a more extensive 
cognitive evaluation than the MMSE in a fairly large study population. Subsequently, it 
would be valuable to monitor how cognition, neuropsychiatric symptoms and ADL change 
with time, and to obtain more information about the usability of the CERAD total score in 
follow-up studies. This kind of follow-up data could also help to find factors that would pre-
dict the progression rate of AD.
    In conclusion, we detected that cognitive performance was not associated with neuro-
psychiatric symptoms, but that ADL were associated with both of these factors. It is evident 215
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that both the cognitive level and neuropsychiatric symptoms affect the patients’ ability to 
cope with the demands in everyday life. Our results help to provide information to patients 
and their caregivers about symptoms during the first years of the disease. Our findings em-
phasize the need for a multifaceted evaluation of AD symptoms in both the clinical and re-
search setting.
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